Science overview

New blood vessels are how disease grows. They're also how it heals.

Angiogenesis is the formation of new blood vessels from existing vasculature. It is essential for embryonic development, wound healing, and reproduction. When dysregulated, it becomes one of the central engines of disease.

In cancer, tumors recruit new vessels to deliver oxygen and nutrients — a hallmark of malignancy first described by Judah Folkman in 1971. In wet age-related macular degeneration, abnormal choroidal vessels destroy central vision. Conversely, in ischemic heart disease, the body's inability to grow new vessels leaves tissue starved of oxygen.

Proposed mechanismAP / 01
01Damaged tissue
02AngioPatch™
03Localized signaling
04Vascular support
05Repair environment

Research-stage platform model · Local delivery · Controlled biological signaling

Mechanism

We design bispecific biologics targeting both VEGF-A and DLL4, disrupting two complementary signaling axes to delay resistance.

Modality

Antibody scaffolds optimized for half-life, tissue penetration, and intravitreal dosing intervals.

Validation

Preclinical models across CRC, NSCLC, and ocular neovascularization. IND-enabling studies underway.

Landscape

Competitive context

CompanyModalityStageStatus
Genentech / RocheMonoclonal antibody (Bevacizumab)Marketed (Avastin)Public
BayerTKI (Regorafenib)MarketedPublic
Regeneron / GenentechProtein decoy (Aflibercept)Marketed (Eylea)Public
AbbVieBispecific (anti-VEGF/DLL4)Phase IIPublic
TRIGR TherapeuticsBispecific (VEGF/DLL4)Phase IPrivate
Angiogenesis ProjectUsBispecific biologic platformPreclinical / INDPrivate

Sources: industry reports; stages illustrative.